Read more

March 02, 2022
1 min read
Save

Top in endocrinology: Gender-affirming care controversy, type 1 diabetes treatments

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The Endocrine Society condemned a new Texas directive that defines gender-affirming care in children, such as reassignment surgeries and hormone treatment, as “child abuse.” It was the top story in endocrinology last week.

Another top story covered promising breakthroughs and achievements in type 1 diabetes treatment, including positive developments in beta-cell regeneration, investigational cell therapy, stem cell transplantation and immunotherapy.

hormone therapy with syringe
Source: Adobe Stock

Read these and more top stories in endocrinology below:

Endocrine Society condemns Texas directive defining gender-affirming care as ‘child abuse’

The Endocrine Society is condemning a new directive issued by Texas Gov. Greg Abbott defining gender care for adolescents as “child abuse,” according to a press release from the organization. Read more.

Approaching a cure: Treatments offer promise to delay, improve life with type 1 diabetes

For people living with type 1 diabetes and the clinicians and researchers who treat and study the disease, 2021 was a year of groundbreaking achievements and cause for optimism. Though as with any new experimental treatments, caveats abound. Read more.

Vitamin D2 supplement may slow progression of new-onset type 1 diabetes in children

A supplement of vitamin D2 may improve insulin sensitivity and slow the increase of HbA1c for children and adolescents with new-onset type 1 diabetes, according to study findings published in the Journal of the Endocrine Society. Read more.

FDA approves first smartphone app for bolus insulin delivery

The FDA has approved the first smartphone application capable of initiating insulin delivery for insulin pump wearers, according to a company press release. Read more.

Telehealth yields weight-loss results during pandemic similar to in-person interventions

Among adults with obesity participating in a telehealth intervention during the COVID-19 pandemic, weight loss was not significantly inferior to that seen with face-to-face programs, according to study data published in Obesity. Read more.